Chugai Pharmaceutical Co., Ltd. has revised the full-year financial forecasts for the fiscal year ending December 2024 announced on February 1, 2024, considering the recent trend of business results, as follows.

1. Revised consolidated financial forecasts for the full fiscal year ending December 2024
(January 1 to December 31, 2024)

2. Reasons for the revisions

Forecast of revenue has been revised to ¥1,150.0 billion, an increase of ¥80.0 billion from the previous forecast. For domestic sales, the revised forecast reflects the progress and revised assumptions for each product including Phesgo, Polivy, Vabysmo and Perjeta. For overseas sales, exports mainly of Hemlibra and Actemra to Roche have been forecasted to be higher than the previous forecast. Additionally, for other revenue, the forecasts for one-time income and royalty, etc. have been updated.

Core operating profit forecast has also been revised to ¥540.0 billion, an increase of ¥80.0 billion from the previous forecast. In addition to the above-mentioned revision of revenue forecast, a lower cost to sales ratio due to a change in the product mix from the previous assumption, etc., foreign exchange effects, and increases in some expenses attributable to increased sales and profits have been included.

Core EPS is forecasted to be ¥236.00, an increase of ¥32.00 from the previous forecast. Since year-end dividend forecast has been revised to Undecided, the forecast for the Core dividend payout ratio has also been revised to Undecided.

The revised full-year consolidated forecasts are based on updated foreign exchange rate assumptions: 1CHF = 161 JPY, 1EUR = 163 JPY, 1USD = 138 JPY, and 1SGD = 113 JPY.